Business Wire

Leading POS Brand Posiflex Wins Prestigious Red Dot Award for New All-in-One Space-Saving POS Terminal


Posiflex Technology, Inc., a global leading brand in the design and manufacture of POS solutions has been recognised by the internationally renowned Red Dot Award: Product Design 2016 for its latest compact, all-in-one POS terminal – model HS-3510W.

This Smart News Release features multimedia. View the full release here:

The HS-3510W is a 10" touch screen terminal ideal for compact counter-tops, integrating a detachable ...

The HS-3510W is a 10" touch screen terminal ideal for compact counter-tops, integrating a detachable printer, optional built-in 2D image scanner and MSR. (Photo: Business Wire)

Held annually since 1955, the Red Dot Award is considered the most valuable accolade for high quality design across different industries. A 41-strong international Red Dot jury evaluates submissions on product ergonomics, functionality and design quality, bestowing the sought-after seal of quality only to those products that stand out clearly from comparable entries thanks to their excellent design.

The newly-launched POS terminal HS-3510W delivers innovation and versatility in a compact and stylish design. Despite its small size, the fanless HS-3510W is a true “all-in-one” POS solution, and the 10” touch-screen terminal integrates the most widely used peripherals in daily POS operation. This includes a detachable 3” thermal printer, optional 2D barcode reader, MSR, fingerprint/ biometric reader, RFID, Wi-Fi module, and customer display.

The HS-3510W similarly delivers when it comes to performance, boasting a powerful Intel Bay Trail quad core processor running up to 2.42 GHz and system memory up to 8GB RAM. Its Projective Capacitive touch screen supports multi-touch functions and the ability to accurately track touches, enabling quick transactions and minimal queuing time. The screen is also adjustable for operators’ ease of use.

With its ultra-small footprint, the HS-3510W is the ultimate space-saving POS touch screen terminal - ideal for use in retail, hospitality, banking, healthcare or any application where space is at a premium. In retail situations, the HS-3510W frees up counter space, enabling retailers to display and promote more merchandise to maximize sales.

The lightweight, wireless HS-3510W can be set up anywhere in temporary or overflow checkout situations such as pop-up stores, high-traffic seasonal sales or other special events. The HS-3510W can also function as a mini-kiosk in both retail and hospitality for loyalty programs, self-service ordering and for looking up information.

Owen Chen, President and CEO at Posiflex Technology, Inc. comments: “After winning this prestigious design award for our mobile POS solution last year, we are delighted to win again in 2016 - this time for our latest, compact all-in-one POS solution HS-3510W.” The ‘Red Dot’ is the most recognised product competition in the world attracting entries from leading global brands, so this award is a testament to the world-class expertise of our in-house designers and our commitment to technological development in POS solutions. The feature-packed HS-3510W is another example of Posiflex driving forward the POS market and setting new standards that deliver in both performance and design.”

About Posiflex

Founded in 1984, Posiflex Technology, Inc. has designed and manufactured its own-branded and world-class POS solutions. Recognized as a pioneer and leader in the industry, Posiflex has been awarded more than 30 patents for innovative design. The company’s products are manufactured in two ISO 9001/9002/14001 facilities in Taiwan and sold worldwide through retail, hospitality, banking, healthcare, kiosks and many other verticals. Posiflex’s offices are in the USA, Germany, China, India, Singapore, Malaysia, Japan, Dubai and Argentina along with the global distribution networks to provide direct and timely support to its customers around the world. For more information:

Contact information

Company contact:
Posiflex Technology, Inc.
+886 (0)2 2299-1599
Press contact:
Posiflex Technology, Inc.
Wei-Lun Chang, +886 (0)2 2299-1599 ext.:182

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Smiths Detection Hold Baggage Scanner Meets Highest Security Standards in EU23.3.2018 07:00Pressemelding

The Smiths Detection HI-SCAN 10080 XCT has achieved ECAC approval as a Standard 3.1 explosives detection system for hold baggage – the highest, defined security standard in the EU. This significant advance was made possible by using a dual-view, dual-energy line scanner with high resolution 3D Computed Tomography (CT) to deliver exceptional data. This press release features multimedia. View the full release here: Smiths Detection HI-SCAN 10080 XCT (Graphic: Business Wire) This achievement gives airports currently upgrading to Standard 3 technology, the option to increase detection levels even further to 3.1; and any standard 3 systems already installed can be easily elevated to 3.1 via a software upgrade. The detection algorithms are interchangeable on a bag by bag basis depending on the destination and associated risk level. This offers additional flexibility and productivity. “With the capability to meet detection requirements